RA Capital
Fuad Naser is an accomplished analyst currently working at RA Capital Management since April 2021, with previous roles as Senior Associate and Associate. Fuad serves as a Board Observer for several companies, including Exo, Nodexus Inc., Ceribell, and Selux Diagnostics, all starting in 2023. Prior to these positions, Fuad earned a Ph.D. in Biological Chemistry from Washington University in St. Louis, where participation in the laboratory of Dr. Gary Patti led to recognition as the winner of the WashU Patent Challenge for RestTest, a diagnostic tool. Experience includes consulting for The BALSA Group, co-founding Edcarta, and a fellowship at Flagship Pioneering as part of the VentureLabs program. Educational background also includes a Bachelor's Degree in Biochemistry and Molecular Biology from the same institution.
RA Capital
2 followers
RA Capital Management® (“RA Capital”) is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics.